Last €2.98 EUR
Change Today -0.015 / -0.50%
Volume 0.0
As of 2:15 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (HTD) Snapshot

Open
€2.94
Previous Close
€3.00
Day High
€2.98
Day Low
€2.94
52 Week High
04/3/14 - €3.19
52 Week Low
05/9/14 - €1.26
Market Cap
301.5M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
101.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORCEPT THERAPEUTICS INC (HTD)

corcept therapeutics inc (HTD) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (HTD) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (HTD) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, an active ingredient in Korlym, which is in Phase III study for treatment of the psychotic features of psychotic depression; and in Phase I study for the treatment of triple-negative breast cancer. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

44 Employees
Last Reported Date: 03/14/14
Founded in 1998

corcept therapeutics inc (HTD) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $925.9K
Chief Financial Officer and Secretary
Total Annual Compensation: $465.4K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $582.6K
Chief Accounting Officer, Vice President and ...
Total Annual Compensation: $328.2K
Consultant
Total Annual Compensation: $679.0K
Compensation as of Fiscal Year 2013.

corcept therapeutics inc (HTD) Key Developments

Corcept Therapeutics Incorporated Announces Sales Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015; Provides Clinical Update

Corcept Therapeutics Incorporated announced sales results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported estimated net revenue of $9.0 million, a 24% increase from the prior quarter and a 119% increase from the same period last year. For the full year, the company reported estimated net revenue of $26.6 million, exceeds 2013 results by 156%. The company estimates 2015 net revenue to be between $47 million and $53 million. The company provided clinical update. It has completed the dose-finding portion of its Phase 1/2 trial of Korlym in combination with eribulin for the treatment of glucocorticoid receptor-positive (GR-positive) TNBC. Recruitment of 20 patients to participate in the trial's efficacy phase is underway. These patients will receive 300 mg of Korlym daily, with eribulin at a dose of 1.1 mg/m2 administered intravenously. Results are expected in 2015. Although the dose-finding phase of the study was designed to assess only safety and tolerability, some preliminary efficacy data are available. Of the six patients in that phase who received the selected dose, three have TNBC. The only patient known to have GR-positive TNBC exhibited a partial response, defined as a 30% or greater reduction in tumor size, and has been on therapy for nine cycles. In contrast, the only patient known to have GR-negative TNBC suffered progression of disease. The trial builds on pre-clinical and clinical research performed by investigators at the University of Chicago and at Corcept showing that Korlym's competitive blockade of GR inhibits TNBC tumor cells from escaping chemotherapy. Corcept has developed a proprietary CLIA-validated diagnostic test for identifying GR-positive tumors. All patients that enroll in the trial's efficacy phase will have GR-positive TNBC.

Corcept Therapeutics Incorporated to Report Q4, 2014 Sales/Trading Statement Results on Jan 29, 2015

Corcept Therapeutics Incorporated announced that they will report Q4, 2014 sales/trading statement results at 9:05 PM, GMT Standard Time on Jan 29, 2015

Corcept Therapeutics Incorporated, Q4 2014 Sales/ Trading Statement Call, Jan 29, 2015

Corcept Therapeutics Incorporated, Q4 2014 Sales/ Trading Statement Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTD:GR €2.98 EUR -0.015

HTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.98.15 CHF +0.75
View Industry Companies
 

Industry Analysis

HTD

Industry Average

Valuation HTD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.